Announcement • 13h
Beijing Tong Ren Tang Chinese Medicine Company Limited Receives Certificate of Registration of Proprietary Chinese Medicine Beijing Tong Ren Tang Chinese Medicine Company Limited has received the Certificate of Registration of Proprietary Chinese Medicine issued by the Chinese Medicine Council of Hong Kong, allowing “Antelope Horn Powder Capsules (Tong Ren Tang) to be sold in the Hong Kong Special Administrative Region of the People’s Republic of China. The relevant details are as follows: Name of the medicine: Antelope Horn Powder Capsules (Tong Ren Tang). Registration number: HKC-18854. Certificate validity period: Until May 21, 2031. The function and main indications of the “Antelope Horn Powder Capsules (Tong Ren Tang)” are indicated for pacifying the liver and extinguishing wind, clearing the liver, improving vision, dissipating blood and removing toxin. It is used for internal stirring of liver wind, fright epilepsy, convulsions, pregnant epilepsy, high fever with convulsions and seizure, epilepsy, manic psychosis, headache, dizziness, red eyes and nebula, macula and papule caused by warm toxin, swelling abscess, sore and skin infections. As of the date of this announcement, the Company has cumulatively invested approximately HKD 1.83 million (unaudited) in the research and development of “Antelope Horn Powder Capsules (Tong Ren Tang)”. This product has not yet been launched for sale in the market. Upon obtaining the Certificate of Registration of Proprietary Chinese Medicine issued by the Chinese Medicine Council of Hong Kong, “Antelope Horn Powder Capsules (Tong Ren Tang)” produced by the Company can be sold in Hong Kong, which is conducive to expanding the product lines of the Company and beneficial to the market expansion of the Company. The obtaining of the aforementioned certificate of registration is not expected to have any material impact on the production, operation and performance of the Company for the time being. The sales of pharmaceutical products can be influenced by factors such as changes in the policy environment, exchange rate fluctuations and market competition in the Hong Kong region. Declared Dividend • Mar 23
Dividend increased to HK$0.40 Dividend of HK$0.40 is 14% higher than last year. Ex-date: 12th June 2026 Payment date: 26th June 2026 Dividend yield will be 5.1%, which is higher than the industry average of 3.6%. Sustainability & Growth Dividend is covered by both earnings (57% earnings payout ratio) and cash flows (56% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 70% over the next 2 years, which should provide support to the dividend and adequate earnings cover. 
